| __timestamp | Geron Corporation | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 5078000000 |
| Thursday, January 1, 2015 | 17793000 | 4717000000 |
| Friday, January 1, 2016 | 18761000 | 5096000000 |
| Sunday, January 1, 2017 | 19287000 | 4986000000 |
| Monday, January 1, 2018 | 18707000 | 4214000000 |
| Tuesday, January 1, 2019 | 20893000 | 3806000000 |
| Wednesday, January 1, 2020 | 25678000 | 3671000000 |
| Friday, January 1, 2021 | 29665000 | 3528000000 |
| Saturday, January 1, 2022 | 43628000 | 3445000000 |
| Sunday, January 1, 2023 | 69135000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Unleashing the power of data
In the pharmaceutical industry, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key indicator of a company's operational focus and market strategy. Over the past decade, Teva Pharmaceutical Industries Limited and Geron Corporation have exhibited contrasting SG&A spending patterns.
From 2014 to 2023, Teva's SG&A expenses have seen a significant reduction of approximately 31%, from $5.08 billion to $3.50 billion. This decline reflects Teva's strategic cost-cutting measures and operational efficiencies in response to market pressures and competitive dynamics.
Conversely, Geron Corporation's SG&A expenses have surged by over 300% during the same period, from $16.76 million to $69.14 million. This increase underscores Geron's aggressive investment in administrative capabilities and market expansion efforts.
These divergent trends highlight the varied strategic priorities and market responses of these two pharmaceutical giants.
Pfizer Inc. and Geron Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Geron Corporation
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation
Cost Management Insights: SG&A Expenses for Incyte Corporation and Geron Corporation
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Geron Corporation
Selling, General, and Administrative Costs: Opthea Limited vs Geron Corporation
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Geron Corporation